Search Results

ACROBiosystems, one of the leading providers of innovative tools and solutions used from discovery to the clinic, has announced a new corporate initiative to support ex vivo cell manufacturing and manufacturers of innovative cell and gene therapies.

ACROBiosystems recently announces the launch of GMP grade DLL4. GMP grade DLL4 is a recombinant, soluble form of Delta-like Ligand 4, or DLL4, that is one of the few products available on the market manufactured under GMP conditions.

ACROBiosystems, through ACRO Certify and under its Aneuro brand, recently announced the launch of in vivo electrophysiology solutions for neuroscience research with Diagnostic Biochips.

With more than 10 years of experience in protein development, ACROBiosystems has continuously demonstrated its strength in developing products and services throughout the entire drug development process.

According to Vision Research Reports, the global cell therapy raw materials market size was valued at USD 3.49 billion in 2022 and it is predicted to surpass around USD 31.28 billion by 2032 with a CAGR of 24.52% from 2023 to 2032. The cell therapy raw materials market in the United States was accounted for USD 1.3 billion in 2022.

According to Nova one advisor, the global Cell-based Assays market size is expected to hit around USD 34.8 billion by 2030 from valued at USD 15.95 billion in 2021 and growing at a CAGR of 8.75% from 2022 to 2030

Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors are defined as medications that have been developed to lower cholesterol levels.

The Viral Antigens market was valued at US$101.41 million in 2019 and is projected to reach US$ 236.80 million by 2027; it is expected to grow at a CAGR of 11.0% during 2020–2027.